bifida occuita; as they had not been subjected to a formal study we do not know whether any of them had neurological defects too minor to warrant clinical referral. In these subjects the bony lesion may not be associated with any nerve deficit, or the absence of associated factors contributing to neurological damage may leave them symptom free.
Despite the significant correlation between the presence of spina bifida occulta and urodynamic abnormalities, no specific correlation was found between the bony defect and any abnormal neurophysiological response. James and Lassman showed in their patients with spina bifida occulta that the neurological lesions were due not to direct interference with nerves in the spina bifida defect but to traction effects from cord tethering or to compression effects on the conus and cauda equina from associated lesions such as lipomas. 4 Similar lesions in our patients may have been contributory in the development of neurogenic defects. Alternatively our results may indicate the lack of any direct association between the radiological and neurophysiological findings and suggest that both are the result of abnormal development of the tail bud in early gestation but that there is no direct causal link. It is important for future studies to establish whether there are lesions in some of these patients causing pressure or traction effects as these lesions may be amenable to surgery.
Abstract
Objective-To determine the optimal duration of antithyroid drug treatment by monitoring serum thyroid stimulating antibody values in patients with Graves' disease.
Design-Prospective longitudinal trial of patients with Graves' disease followed up for 24 months after withdrawal of treatment.
Setting-Tertiary referral centre. Patients-A total of 64 consecutive patients with untreated Graves' disease, eight of whom were subsequently excluded. Fifty six patients completed the study.
Interventions-All patients were treated initially with carbimazole 40 Conclusion-Monitoring of serum thyroid stimulating antibody was a good guide to the duration of treatment as it allowed the treatment period to be considerably shortened in a large group of patients with no loss of efficiency.
Introduction
Patients with Graves' disease may be treated with ablative or non-ablative treatment. Thyroidectomy is rapid and radioactive iodine treatment simple for the patient; both are effective in the long term but carry an obvious risk of hypothyroidism.'3 Non-ablative treatment with antithyroid drugs is less efficient but preferred by many as the best choice for new patients because it is well tolerated and does not carry the risk of secondary hypothyroidism.45 Both short term67 and long term89 treatments have been proposed. We aimed at determining whether drug treatment could be stopped more appropriately when serum thyroid stimulating antibody became undetectable.
Patients and methods
Patients -Sixty four untreated patients with Graves' disease diagnosed by clinical signs of hyperthyroidism accompanied by increased thyroid hormone concentrations (free triiodothyronine >8 *9 pmol/l; free thyroxine >23 4 pmol/l) and homogeneous thyroid scans were entered consecutively into the study from July 1983 to June 1985. Eight patients were subsequently excluded BMJ VOLUME 298
11 FEBRUARY 1989 359 for the following reasons: serum thyroid stimulating antibody was absent before treatment (three), patients chose surgery before three months of drug treatment had been completed (two), patients left follow up (three). A total of 56 patients remained in the study, consisting of 40 women and 16 men, median age 41, range 18-67.
Treatment and follow up-All patients were treated with carbimazole, initially at a high dose (40 mg a day) followed by decreasing doses that maintained a euthyroid state without hormone replacement. During the treatment protocol patients were seen every three months. After withdrawal of the drug they were recalled every six months for 24 months for physical examinations and assays of free triiodothyronine, thyroxine, thyroid stimulating hormone, and thyroid stimulating antibody concentrations. Patients were also seen in cases of a relapse. Previously we had treated our patients routinely for 18 
Results
Of the 56 patients, 44 (79%) without detectable thyroid stimulating antibody before the end of the treatment period were assigned to one group and the 12 (21%) in whom the assay remained positive at the end of the 18 months' treatment were assigned to another group. Patients in both groups were not significantly different in age, sex, or initial thyroid hormone concentrations (table I). In the first group treatment lasted a median of 9 (range 3-18) months. In all of these the median duration of treatment was nine months shorter than the standard 18 months.
The relapse rate in patients with detectable thyroid stimulating antibody was significantly increased (92% v 41%; y2=9*72, df=1, p<OOOl). In patients without detectable antibody the relapse rate was independent of duration of treatment (y2=2-25, df=4) (table II) . 
Discussion
This is the first prospective longitudinal study designed to evaluate the value of thyroid stimulating antibody assay in determining the duration of drug treatment in Graves' disease. Thyroid stimulating antibodies are highly specific for Graves' disease and their value usually decreases during treatment.' Our assay is very sensitive, giving positive results in 95% of untreated cases. Our findings support the hypothesis that repeated assay of thyroid stimulating antibody could give valuable information concerning the best time to withdraw antithyroid drugs: the rate of relapse in patients whose drug treatment was withdrawn when the assay gave negative results was significantly lower (41%) than that in patients whose treatment was withdrawn after a fixed course of 18 months despite positive results for thyroid stimulating antibody (9 1% ). The rate of relapse and the disease free interval were not correlated with the time it took for the antibody to become negative. With a negative test result for thyroid stimulating antibody as the signal to stop the antithyroid drug treatment the duration of treatment was significantly reduced (median reduction nine months for 56 patients in our series). A low initial value for thyroid stimulating antibody before treatment predicted early remission.
Randomised prospective studies have shown a correlation between remission rates and duration of treatment; in patients treated for six months the rates were 31%" and 417%,'" whereas treatment for 18 months to two years increased the rates to 79%' and 61 8%."' These results are consistent with our findings as the proportion of patients without detectable thyroid stimulating antibody increased from 37% at six months to 79% at 18 months. Remission rates and doses of antithyroid drugs for a fixed period are directly correlated. The '9 In fact, the presence of thyroid stimulating antibody is only a marker ofimmunological activity responsible for hyperthyroidism. We think, therefore, that thyroid stimulating antibody values are a useful guide to the duration of treatment, as their monitoring allowed the treatment period to be considerably shortened in a large group of patients with no loss of efficiency.
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